Who has been buying Kangstem Biotech stock?

11 distinct insiders have filed 27 disclosed insider purchases in Kangstem Biotech (217730), most recently on 2026-02-03. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Kangstem Biotech have?

Kangstem Biotech has 27 buy-side and 7 sell-side disclosures on record, covering ₩3.8B ($2.6M) in total reported value, spanning 2024-05-10 to 2026-02-03.

Where does StockDrifts get Kangstem Biotech insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Kangstem Biotech 217730

Company

강스템바이오텍Kangstem Biotech

Insiders

Buys

Total Value

₩3.8B ($2.6M)

Avg Return

+14.40%

Last Filing

2026-02-03

Kangstem Biotech (217730) has 27 disclosed insider purchases and 7 disclosed disposals on record, filed by 11 distinct insiders. Together those filings cover ₩3.8B ($2.6M) in reported transaction value. The earliest filing StockDrifts holds for Kangstem Biotech is dated 2024-05-10; the most recent is 2026-02-03. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +14.40%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-02-03	BUY	PROGRAM	유연실 Flexible room	Managing Director	1.3K	₩2,090	+9.6%	₩3M ($2K)
2026-02-03	BUY	PROGRAM	어해관 fish customs	Managing Director	1.5K	₩2,090	+9.6%	₩3M ($2K)
2026-02-03	BUY	PROGRAM	이승희 Seunghee Lee	Internal director	2.0K	₩2,090	+9.6%	₩4M ($3K)
2026-02-02	BUY	PROGRAM	이계종 Different species	Managing Director	6.0K	₩2,145	+6.8%	₩13M ($9K)
2026-01-30	BUY	PROGRAM	나종천 Na Jong-cheon	CEO	20.0K	₩2,195	+4.3%	₩44M ($30K)
2026-01-30	BUY	PROGRAM	김원균 Kim Won-gyun	Internal director	4.0K	₩2,195	+4.3%	₩9M ($6K)
2026-01-30	BUY	PROGRAM	배요한 Yohan Bae	Managing Director	10.6K	₩2,195	+4.3%	₩23M ($16K)
2026-01-30	BUY	PROGRAM	이계종 Different species	Managing Director	4.0K	₩2,195	+4.3%	₩9M ($6K)
2025-08-26	SELL	기타	배요한 Yohan Bae	Managing Director	-24.7K	₩1,309	-74.9%	₩32M ($22K)
2025-08-26	SELL	기타	어해관 fish customs	Managing Director	-4.2K	₩1,309	-74.9%	₩5M ($4K)
2025-08-26	SELL	기타	김원균 Kim Won-gyun	Internal director	-4.3K	₩1,309	-74.9%	₩6M ($4K)
2025-08-26	SELL	기타	나종천 Na Jong-cheon	CEO	-75.7K	₩1,309	-74.9%	₩99M ($69K)
2025-08-26	SELL	기타	이승희 Seunghee Lee	Internal director	-6.1K	₩1,309	-74.9%	₩8M ($6K)
2025-08-26	BUY	PROGRAM	이승희 Seunghee Lee	Internal director	7.0K	₩1,309	+74.9%	₩9M ($6K)
2025-08-26	SELL	기타	이승희 Seunghee Lee	Internal director	-7.0K	₩1,309	-74.9%	₩9M ($6K)
2025-08-26	BUY	PROGRAM	나종천 Na Jong-cheon	CEO	86.9K	₩1,309	+74.9%	₩114M ($79K)
2025-08-26	BUY	PROGRAM	김원균 Kim Won-gyun	Internal director	4.9K	₩1,309	+74.9%	₩6M ($4K)
2025-08-26	BUY	PROGRAM	어해관 fish customs	Managing Director	4.8K	₩1,309	+74.9%	₩6M ($4K)
2025-08-26	BUY	PROGRAM	배요한 Yohan Bae	Managing Director	28.4K	₩1,309	+74.9%	₩37M ($26K)
2025-08-26	BUY	PROGRAM	최정호 Jeongho Choi	Other non-executive directors	66.2K	₩1,309	+74.9%	₩87M ($60K)
2025-08-26	BUY	PROGRAM	이계종 Different species	Managing Director	18.8K	₩1,309	+74.9%	₩25M ($17K)
2025-08-26	BUY	PROGRAM	강경선 Kang Kyung-seon	-	534.6K	₩1,309	+74.9%	₩700M ($486K)
2025-08-26	SELL	기타	세종 Sejong	-	-9.3M	₩1,309	-74.9%	₩12.1B ($8.4M)
2025-08-26	SELL	기타	강경선 Kang Kyung-seon	-	-534.6K	₩1,309	-74.9%	₩700M ($486K)
2025-08-26	SELL	기타	이미혜 Mihye Lee	Managing Director	-19.7K	₩1,309	-74.9%	₩26M ($18K)
2025-08-26	SELL	기타	이미혜 Mihye Lee	Managing Director	-4.1K	₩1,309	-74.9%	₩5M ($4K)
2025-08-26	SELL	기타	유연실 Flexible room	moving	-1.0K	₩1,309	-74.9%	₩1M ($920)
2025-08-26	SELL	기타	이계종 Different species	Managing Director	-16.3K	₩1,309	-74.9%	₩21M ($15K)
2025-08-26	SELL	기타	최정호 Jeongho Choi	Other non-executive directors	-66.2K	₩1,309	-74.9%	₩87M ($60K)
2025-08-26	BUY	유상신주취득	세종 Sejong	-	10.6M	₩1,309	+74.9%	₩13.9B ($9.7M)
2025-08-26	BUY	PROGRAM	유연실 Flexible room	moving	1.2K	₩1,309	+74.9%	₩2M ($1K)
2025-08-26	BUY	PROGRAM	이미혜 Mihye Lee	Managing Director	19.7K	₩1,309	+74.9%	₩26M ($18K)
2025-08-07	BUY	Market Buy	세종 Sejong	-	30.0K	₩1,340	+70.9%	₩40M ($28K)
2025-08-06	SELL	Market Sell	최정호 Jeongho Choi	Other non-executive directors	-66.2K	₩1,353	-69.3%	₩90M ($62K)
2025-08-06	BUY	Market Buy	세종 Sejong	-	324.1K	₩1,353	+69.3%	₩439M ($305K)
2025-08-05	BUY	장외매수	세종 Sejong	-	1.2M	₩1,353	+69.3%	₩1.7B ($1.2M)
2025-08-05	SELL	장외매도	강경선 Kang Kyung-seon	-	-1.2M	₩1,353	-69.3%	₩1.7B ($1.2M)
2025-08-04	BUY	Market Buy	세종 Sejong	-	400.0K	₩1,360	+68.4%	₩544M ($378K)
2025-08-01	BUY	Market Buy	세종 Sejong	-	1.8M	₩1,326	+72.7%	₩2.4B ($1.7M)
2025-07-23	BUY	PROGRAM	이승희 Seunghee Lee	Internal director	13.1K	₩1,400	+63.6%	₩18M ($13K)
2025-07-23	BUY	PROGRAM	최정호 Jeongho Choi	Other non-executive directors	132.4K	₩1,400	+63.6%	₩185M ($129K)
2025-07-23	BUY	PROGRAM	이계종 Different species	Managing Director	16.3K	₩1,400	+63.6%	₩23M ($16K)
2025-07-23	BUY	PROGRAM	이미혜 Mihye Lee	Managing Director	23.7K	₩1,400	+63.6%	₩33M ($23K)
2025-07-23	BUY	기타	세종 Sejong	-	5.4M	₩1,400	+63.6%	₩7.6B ($5.3M)
2025-07-23	BUY	PROGRAM	유연실 Flexible room	moving	1.0K	₩1,400	+63.6%	₩1M ($984)
2025-07-23	BUY	PROGRAM	강경선 Kang Kyung-seon	-	1.8M	₩1,400	+63.6%	₩2.5B ($1.7M)
2025-07-23	BUY	PROGRAM	김원균 Kim Won-gyun	Internal director	4.3K	₩1,400	+63.6%	₩6M ($4K)
2025-07-23	BUY	PROGRAM	나종천 Na Jong-cheon	CEO	75.7K	₩1,400	+63.6%	₩106M ($74K)
2025-07-23	BUY	PROGRAM	어해관 fish customs	Managing Director	4.2K	₩1,400	+63.6%	₩6M ($4K)
2025-07-23	BUY	PROGRAM	배요한 Yohan Bae	Managing Director	24.7K	₩1,400	+63.6%	₩35M ($24K)

Showing the 50 most recent of 71 filings.

Frequently asked questions

Who has been buying Kangstem Biotech stock?: 11 distinct insiders have filed 27 disclosed insider purchases in Kangstem Biotech (217730), most recently on 2026-02-03. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Kangstem Biotech have?: Kangstem Biotech has 27 buy-side and 7 sell-side disclosures on record, covering ₩3.8B ($2.6M) in total reported value, spanning 2024-05-10 to 2026-02-03.
Where does StockDrifts get Kangstem Biotech insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Kangstem Biotech. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.